Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis
Gail P Risbridger, Renea A Taylor, David Clouston, Ania Sliwinski, Heather Thorne, Sally Hunter, Jason Li, Gillian Mitchell, Declan Murphy, Mark Frydenberg, David Pook, John Pedersen, Roxanne Toivanen, Hong Wang, Melissa Papargiris, Mitchell G Lawrence, Damien M Bolton
Eur Urol | ELSEVIER | Published : 2015
BACKGROUND: Intraductal carcinoma of the prostate (IDC-P) is a distinct clinicopathologic entity associated with aggressive prostate cancer (PCa). PCa patients carrying a breast cancer 2, early onset (BRCA2) germline mutation exhibit highly aggressive tumours with poor prognosis. OBJECTIVE: To investigate the presence and implications of IDC-P in men with a strong family history of PCa who either carry a BRCA2 pathogenic mutation or do not carry the mutation (BRCAX). DESIGN, SETTING, AND PARTICIPANTS: Patient-derived xenografts (PDXs) were generated from three germline BRCA2 mutation carriers and one BRCAX patient. Specimens were examined for histologic evidence of IDC-P. Whole-genome copy n..View full abstract
Awarded by Cancer Council Tasmania and Cancer Australia
Awarded by National Health and Medical Research Council Early Career Fellowship
Awarded by National Breast Cancer Foundation
Funding for the design and conduct of this study included contributions from the Peter and Lyndy White Foundation, Victorian Cancer Agency (CAPTIV Collaborative Grant), and Cancer Council Tasmania and Cancer Australia (ID: 1006349). Mitchell G. Lawrence is the recipient of a National Health and Medical Research Council Early Career Fellowship (1035721) and Movember Young Investigator award from the Prostate Cancer Foundation of Australia. kConFab is supported by a grant from the National Breast Cancer Foundation.